Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Holding APLS?
Track your performance easily
APLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.34 - $71.90
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.21M
Market Cap
$3.73B
Enterprise Value$3.66B
Total Cash (Recent Filing)$24.86M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Mar 04, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding124,393,020
10 Day Avg. Volume1,992,189
30 Day Avg. Volume2,213,686
Standard Deviation0.21
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.22
Price to Cash Flow (P/CF)27.40
P/FCF Ratio27.40
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue5.11
Enterprise Value/Gross Profit10.81
Enterprise Value/Ebitda-17.37
Forecast
1Y Price Target
$43.53Price Target Upside50.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Apellis Pharmaceuticals News
PremiumCompany Announcements
Apellis Pharmaceuticals Reports Strong Growth and Leadership ChangesBulls Say, Bears Say
Bulls Say
Market PositioningA large Medicare Advantage plan recently made Syfovre the only preferred product on its formulary, indicating strong market positioning.
Product ApprovalApproval in Australia marks first ex-US approval of any GA treatment.
Sales PerformanceSyfovre's sales performance improved in 4Q, representing a 6.5% increase, and came out ahead of consensus estimates.
Bears Say
Financial PerformanceEmpaveli sales missed expectations, which may signal challenges in meeting market demands or forecasts.
Market GrowthThe company acknowledged challenges in the geographic atrophy market growth, which impacts near-term stock performance.
Sales And RevenueApellis reported 3Q24 results, including a sequentially lower Syfovre revenue quarter on modest vial growth but lower net price and increased competition.
---
Ownership Overview
3.21% Insiders
27.77% Mutual Funds
0.11% Other Institutional Investors
54.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $24.34 and its highest was $71.90 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $3.73B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2025 which is in 31 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Nov 05, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.165.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.36.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 124,393,020 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -1.681%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Apellis Pharmaceuticals Inc’s shares valued at 5M.
---
Apellis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.53 (50.05% Upside)
$43.53 (50.05% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 7.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.90%
12-Months-Change
Fundamentals
Return on Equity
-105.47%
Trailing 12-Months
Asset Growth
10.22%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong demand growth for SYFOVRE and promising Phase III results for Empaveli, indicating potential for significant market impact. However, these positives were offset by revenue decline for SYFOVRE due to gross to net adjustments, slowed market growth, and challenges in Europe. Overall, the company remains optimistic about long-term prospects and profitability but faces immediate hurdles.Read More>---
APLS Stock 12 Month Forecast
Average Price Target
$43.53
▲(50.05% Upside)
Technical Analysis
Alnylam Pharma
―
Neurocrine
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering APLS
1 Year
1 Year Success Rate
15/29 ratings generated profit
1 Year Average Return
+8.12%
reiterated a buy rating 20 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 51.72% of your transactions generating a profit, with an average return of +8.12% per trade.
---